The company believes its DLL3-targeting ADC could be fast tracked despite the presence of Imdelltra.

And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.

Yet more data validate B7-H3, and put MediLink in the deal-making frame.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.

A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?

The company defends its cancer strategy, and says it's not a me-too developer.